Search…

Lilly's (LLY.US) oral weight loss drug Phase III data released: average weight loss of 10.5%, will initiate global filing.

26/08/2025

According to the Zhitong Financial APP, Eli Lilly (LLY.US) announced on Tuesday that its oral weight loss therapy orforglipron has achieved its main goal in the Phase 3 clinical trial. The company will now proceed with global registration applications for this once-daily GLP-1 receptor agonist.

Latest

1 m ago

The MSCI China Index has risen by over 30% since the beginning of this year. The adjustment of the MSCI China Index officially took effect.

2 m ago

Hainan Haiyao: Net loss attributable to mother in the first half of the year was 158 million yuan.

2 m ago

Qingdao Beer Co., Ltd. (00168.HK) announced its interim results, with a net profit of approximately 3.904 billion yuan attributable to the parent company, representing a year-on-year growth of 7.21%.

2 m ago

Fu Rong Technology's net profit in the first half of the year decreased by 60% year-on-year. The company secretary said it was mainly due to losses from its subsidiaries.

2 m ago

Lingbao Gold (03330.HK) released its interim results, with a net profit attributable to shareholders of 664 million yuan, representing a year-on-year increase of 335.28%. The interim dividend is 0.164 yuan per share.

See all latest